Finland· FI-REL-REL43646
Entyvio
A vedolizumab product containing vedolizumab, registered in Finland by Takeda Pharma A/S. The same ATC class is registered in 12 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Vedolizumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG05 (vedolizumab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Vedolizumab · ATC L04AG05
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vedolizumab costs, country by country.
Normalised to the WHO defined daily dose (5.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Vedolizumab · price per daily dose (5.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$36.68
The record
At a glance
Fimea (Finland)- Active substance
- Vedolizumab
- Manufacturer
- Takeda Pharma A/S
- Country
- Finland (FI)
- ATC code
- L04AG05
- ATC class
- Vedolizumab
- Defined daily dose
- 5.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa431978300 mgEUR 3531.12
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
60 interactions on record for vedolizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vedolizumab · interactions on record
60 records
- 27 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vedolizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomEntyvio 300mg powder for concentrate for solution for infusion vialsTakeda UK Ltd
- SpainENTYVIO 300 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONTakeda Pharma A/S
- IcelandEntyvioTakeda Pharma A/S
- NorwayEntyvioTakeda Pharma A/S (1)
- PolandEntyvioTakeda Pharma A/S
- BelgiumEntyvio 300 mgTakeda Pharma
- SwedenEntyvio 300 mg Pulver till koncentrat till infusionsvätska, lösningTakeda Pharma A/S
- CzechiaENTYVIOTakeda Pharma A/S, Vallensbaek Strand
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Entyvio
- Liechtenstein · Entyvio
- Norway · Entyvio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf4e30d6-3543-49a6-bbc4-cca676293c30 GET /v1/drugs/bf4e30d6-3543-49a6-bbc4-cca676293c30?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "5.4",
"form": "kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos",
"route": "Laskimoon",
"ddd_unit": "mg",
"strength": "300 mg",
"atc_label": "vedolitsumabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/14/923/001",
"fimea_rel_id": "REL43646",
"authorised_at": "2014-05-22"
}See everything about vedolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.